VIR logo

VIR
Vir Biotechnology Inc

6,483
Mkt Cap
$1.05B
Volume
12.32M
52W High
$9.84
52W Low
$4.16
PE Ratio
-2.09
VIR Fundamentals
Price
$7.43
Prev Close
$7.56
Open
$7.54
50D MA
$6.75
Beta
1.54
Avg. Volume
1.99M
EPS (Annual)
-$3.83
P/B
1.32
Rev/Employee
$181,875.00
$103.21
Loading...
Loading...
News
all
press releases
Vir Biotechnology (NASDAQ:VIR) Releases Earnings Results, Beats Expectations By $0.11 EPS
Vir Biotechnology (NASDAQ:VIR - Get Free Report) issued its earnings results on Monday. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.11...
MarketBeat·41m ago
News Placeholder
More News
News Placeholder
Vir Biotechnology (VIR) Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·1h ago
News Placeholder
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. This is a seminal moment for Vir...
Business Wire·4h ago
News Placeholder
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell...
Business Wire·4h ago
News Placeholder
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer Astellas and Vir...
PR Newswire·4h ago
News Placeholder
A Glimpse of Vir Biotechnology's Earnings Potential
read more...
Benzinga·3d ago
News Placeholder
Aberdeen Group plc Purchases 519,374 Shares of Vir Biotechnology, Inc. $VIR
Aberdeen Group plc lifted its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 51.6% in the third quarter, according to the company in its most recent 13F filing with the Securities...
MarketBeat·4d ago
News Placeholder
Brent Sabatini Sells 1,530 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CAO Brent Sabatini sold 1,530 shares of Vir Biotechnology stock in a transaction that occurred on Friday, February 13th. The shares were sold at...
MarketBeat·5d ago
News Placeholder
Vir Biotechnology (NASDAQ:VIR) CAO Brent Sabatini Sells 1,530 Shares
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CAO Brent Sabatini sold 1,530 shares of the company's stock in a transaction dated Friday, February 13th. The stock was sold at an average price...
MarketBeat·5d ago
News Placeholder
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat...
MarketBeat·7d ago
<
1
2
...
>

Latest VIR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.